Watch INMB. Know when insiders buy.
One email the day a filing lands. Free.
INMB
Inmune Bio, Inc.
2.05
−0.21 −9.29%
USD · close Sep 16
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
41
WATCH · shorts 41
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $56.9MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$18.4MNET CASH $9.8M52W 1.12 – 2.51SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$1.5M | −$1.3M | — | -0.05 | −$3.2M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$5.8M | −$5.4M | — | -0.20 | −$3.4M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$5.5M | −$5.3M | — | -0.18 | −$2.9M | $143K | −$3.1M | Mar 30 |
| Q3 2025 · Sep 30 | $0 | — | — | −$7.4M | −$6.5M | — | -0.24 | −$5.4M | $193K | −$5.6M | Oct 30 |
| Q2 2025 · Jun 30 | $0 | — | — | −$24.6M | −$24.5M | — | -1.05 | −$7.4M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | $50K | +257.1% | — | −$9.9M | −$9.7M | — | -0.43 | −$6.8M | — | — | Aug 6 |
| Q4 2024 · Dec 31derived | $0 | −100.0% | — | −$9.5M | −$9.2M | — | -0.40 | −$11M | — | — | Mar 30 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$12.3M | −$12.1M | — | -0.60 | −$7M | — | — | Oct 30 |
| Q2 2024 · Jun 30 | $0 | — | — | −$9.9M | −$9.7M | — | -0.50 | −$7.9M | — | — | Oct 30 |
| Q1 2024 · Mar 31 | $14K | — | — | −$11M | −$11M | — | -0.61 | −$7.5M | — | — | Oct 30 |
| Q4 2023 · Dec 31derived | $28K | — | — | −$8.4M | −$8.4M | — | -0.47 | −$3.4M | — | — | Mar 27 |
| Q3 2023 · Sep 30 | $43K | — | — | −$8.5M | −$8.6M | — | -0.48 | −$4.3M | — | — | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $50K | — | −$47.4M | −$45.9M | -91866.0% | -1.86 | −$22.6M | $1M | −$23.6M | — | — |
| FY2024 · to Dec 31 | $14K | — | −$42.6M | −$42.1M | -300585.7% | -2.11 | −$33.4M | — | — | — | — |
| FY2023 · to Dec 31 | $155K | — | −$29.7M | −$30M | -19360.0% | -1.67 | −$12M | — | — | — | — |
| FY2022 · to Dec 31 | $374K | — | −$26M | −$27.3M | -7299.2% | -1.52 | −$22.7M | — | — | — | — |
| FY2021 · to Dec 31 | $181K | — | −$29.2M | −$30.3M | -16762.4% | -1.88 | −$28.5M | — | — | — | — |
| FY2020 · to Dec 31 | $11K | — | −$12.2M | −$12.1M | -109990.9% | -1.01 | −$8.9M | — | — | — | — |
Every number comes from Inmune Bio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.